UNI-EN 154:Notification_Operational program_2013
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 154 | / | 2013 | | ||||||
| Date of issue: | 2013-12-09 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Notification_Operational program_2013 | |||||||||||
| Official market - legal basis | |||||||||||
| Inne uregulowania | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Sopharma AD (the “Company") notifies that today, 9 December 2013, the Company received official confirmation from the Ministry of Economy and Energy that the project "Implementation of innovative products in the ampoule production of Sopharma AD" under Operational Program "Development of the Competitiveness of the Bulgarian Economy" 2007-2013 was ranked 5th on the list of largest companies. The project is included in the list of project proposals approved for funding under the above procedure, with a maximum grant financing of 3,000,000 BGN. The total cost of the project is 6,063,073 BGN (excl. VAT). The project is aimed at the acquisition and commissioning of: 1) a line for automatic grading of ampoules consisting of a machine for visual inspection and a module for 100% quality control and hermeticity check through high-voltage arc and 2) a line for interior and exterior wash, dry sterilization (depyrogenation), filling and soldering of ampoules with gassing with nitrogen. The total duration of the project will be 18 months. The next step is the signing of a contract for grant financing by the end of 2013 . | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Notification_Operational program_2013.doc Notification_Operational program_2013.doc | Notification_Operational program_2013 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-12-09 | Ognian Donev | Executive director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
